Huadong Medicine Co Ltd
SZSE:000963
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.38
38.98
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Huadong Medicine Co Ltd
Huadong Medicine Co Ltd
Cash from Operating Activities
Huadong Medicine Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Cash from Operating Activities
¥4.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
22%
|
CAGR 10-Years
12%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Cash from Operating Activities
¥19.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
62%
|
CAGR 10-Years
13%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Cash from Operating Activities
¥5.7B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
17%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Cash from Operating Activities
¥1.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Cash from Operating Activities
¥1.7B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
|
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
Cash from Operating Activities
¥2.8B
|
CAGR 3-Years
43%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Huadong Medicine Co Ltd
Glance View
Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.
See Also
What is Huadong Medicine Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
4.2B
CNY
Based on the financial report for Sep 30, 2024, Huadong Medicine Co Ltd's Cash from Operating Activities amounts to 4.2B CNY.
What is Huadong Medicine Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
12%
Over the last year, the Cash from Operating Activities growth was 26%. The average annual Cash from Operating Activities growth rates for Huadong Medicine Co Ltd have been 5% over the past three years , 22% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet